ライフサイエンスコーパス: retinal vein occlusion

1 s can be an innovative tool in management of retinal vein occlusion.

2 eneration (AMD), diabetic macular edema, and retinal vein occlusion.

3 cular degeneration, diabetic maculopathy, or retinal vein occlusion.

4 eovascularization in the pig model of branch retinal vein occlusion.

5 he treatment of macular edema due to central retinal vein occlusion.

6 cluded from the therapy approval studies for retinal vein occlusion.

7 and treatment of recurrent macular edema in retinal vein occlusion.

8 quantify macular edema in central and branch retinal vein occlusion.

9 improving visual acuity in participants with retinal vein occlusion.

10 efield angiogram images of eyes with central retinal vein occlusion.

11 edema secondary to either central or branch retinal vein occlusion.

12 egeneration or macular edema attributable to retinal vein occlusion.

13 oliferative diabetic retinopathy and central retinal vein occlusion.

14 ge-related macular degeneration, and central retinal vein occlusions.

15 nsive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retini

16 s in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with co

17 s in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2).

18 ) in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2); evaluate the baseline

19 ration: 34.2 %; diabetic retinopathy: 4.2 %; retinal vein occlusion: 3.8 %).

20 rtery occlusion (4/16), and isolated central retinal vein occlusion (4/16).

21 ction (5 with central and 2 with hemicentral retinal vein occlusion), 4 eyes were unremarkable at pre

22 tinal artery occlusion and 463 patients with retinal vein occlusion, 66 (58.4%) and 245 (52.9%) were

23 contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter tr

24 derived anatomic measurements between branch retinal vein occlusion and central retinal vein occlusio

25 e main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema.

26 In patients with central retinal vein occlusion and initially low visual acuity,

27 thickness in patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in c

28 sc were made for 13 patients with DE (7 with retinal vein occlusions and 6 with inflammatory optic ne

29 ckings (AVNs) in the retina are the cause of retinal vein occlusions and are also surrogates of cereb

30 ortant implications for the understanding of retinal vein occlusions and of cerebrovascular aging.

31 discussing the prognosis and risk factors of retinal vein occlusions and the treatment options.

32 , diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes.

33 , in models of retinal degeneration, central retinal vein occlusion, and oxygen-induced retinopathy.

34 such as proliferative diabetic retinopathy, retinal vein occlusion, and retinal detachment, than in

35 omplication of retinal ischemia in diabetes, retinal vein occlusion, and retinopathy of prematurity.

36 nal diseases including diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity.

37 erative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses.

38 sive patient, who developed bilateral branch retinal vein occlusion at 6T, the therapy was discontinu

39 betic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO).

40 patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein

41 In retinal vein occlusion, both ranibizumab and Ozurdex hav

42 tral retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causes hypoperfusion, high

43 ral retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) complicated by macular ede

44 olume distensibility in patients with branch retinal vein occlusion (BRVO) in comparison with normal

45 natural history of visual outcome in branch retinal vein occlusion (BRVO) is fundamental to its mana

46 Branch retinal vein occlusion (BRVO) is second only to diabetic

47 optic nerve head (ONH) parameters and branch retinal vein occlusion (BRVO) using spectral domain opti

48 venous crossings are risk factors for branch retinal vein occlusion (BRVO), an eye disease in which c

49 ent due to macular edema secondary to branch retinal vein occlusion (BRVO).

50 ative diabetic retinopathy (PDR), and branch retinal vein occlusion (BRVO).

51 nt of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

52 ection for macular edema secondary to branch retinal vein occlusion (BRVO).

53 ) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

54 pth (VCD) and both central (CRVO) and branch retinal vein occlusions (BRVO) using optical low coheren

55 n occlusion [CRVO]) and 17.4 to 19.1 (branch retinal vein occlusion [BRVO]).

56 ab and steroid implants can be considered in retinal vein occlusion, but trials are awaited to determ

57 ration (nAMD), diabetic macular edema (DME), retinal vein occlusion, choroidal neovascularization (CN

58 ular diseases (e.g., diabetic macular edema, retinal vein occlusion, choroidal neovascularization) ha

59 pain score) and similar to patients in other retinal vein occlusion clinical trials.

60 uently developed retinal artery occlusion or retinal vein occlusion compared with patients undergoing

61 the amount of neovascularization induced by retinal vein occlusion, corneal growth factor pellets, a

62 aphy angiography (OCTA) in eyes with central retinal vein occlusion (CRVO) and branch retinal vein oc

63 o review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of n

64 To determine the outcome of central retinal vein occlusion (CRVO) in pre-existing glaucoma a

65 Central retinal vein occlusion (CRVO) or branch retinal vein occ

66 ents with macular edema secondary to central retinal vein occlusion (CRVO) or hemiretinal vein occlus

67 ble to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlus

68 fty-five patients with a nonischemic central retinal vein occlusion (CRVO) who were randomized to rec

69 To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recen

70 ers a distinctive retinopathy with a central retinal vein occlusion (CRVO)-like appearance.

71 perfused macular edema in eyes with central retinal vein occlusion (CRVO).

72 nch retinal (BRVO), hemi-retinal and central retinal vein occlusion (CRVO).

73 CG) in eyes with the recent onset of central retinal vein occlusion (CRVO).

74 etic macular edema (DME), central and branch retinal vein occlusion (CRVO/BRVO), central serous chori

75 at 6 and 12 months was 15.0 to 16.5 (central retinal vein occlusion [CRVO]) and 17.4 to 19.1 (branch

76 retinopathy, glaucoma, and branch or central retinal vein occlusion diagnosis.

77 ve (2/26), and neovascular following central retinal vein occlusion from amyloidosis (1/26).

78 and the absence of such a difference in the retinal vein occlusion group could be explained by edema

79 = 0.024); however, the same analysis in the retinal vein occlusion group revealed no significant dif

80 en branch retinal vein occlusion and central retinal vein occlusion groups (all P >/= 0.058); therefo

81 Patients with retinal vein occlusion had higher risks of hemorrhagic s

82 to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of less than

83 eneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).

84 r managing complications of ischemic central retinal vein occlusion (iCRVO).

85 ged 18 years with macular edema secondary to retinal vein occlusion in the branch vein occlusion (BRA

86 Retinal vein occlusion is a common retinal vascular diso

87 Retinal ischemic damage associated with retinal vein occlusion is exacerbated by fluid extravasa

88 cation of diabetes mellitus, prematurity, or retinal vein occlusion, is a major cause of blindness wo

89 In eyes with retinal vein occlusion, longer ME duration at the time o

90 ve of best-corrected visual acuity (BCVA) in retinal vein occlusion macular edema (RVO-ME).

91 g, contralateral PCME, diabetic retinopathy, retinal vein occlusion, macular hole, epiretinal membran

92 pressure in the cat after acute experimental retinal vein occlusion may define the role of intravascu

93 h retinal arterial occlusion (n = 3), branch retinal vein occlusion (n = 1), vitamin A deficiency (n

94 , diarrhoea, myocardial infarction, pyrexia, retinal vein occlusion, n=1 each; placebo: vomiting, whi

95 Cystoid macular edema in retinal vein occlusion occurred in relation to altered i

96 caused by inflammatory optic neuropathies or retinal vein occlusions on optical coherence tomography

97 , leakage such as macular edema secondary to retinal vein occlusion, or a combination of proliferatio

98 This suggests that prompt treatment for retinal vein occlusion, particularly BRVO, may be associ

99 retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 i

100 CE PATTERN(R) GUIDELINES: New evidence-based Retinal Vein Occlusions Preferred Practice Pattern(R) (P

101 RETINAL VEIN OCCLUSIONS PREFERRED PRACTICE PATTERN(R) GU

102 agent ranibizumab in diabetic macular edema, retinal vein occlusion, pseudophakic macular edema, and

103 diverse conditions as diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, exud

104 E (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein occlusion (RR 12.9), macular hole (RR 7.7),

105 .07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or

106 R), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxi

107 Macular oedema secondary to retinal vein occlusion (RVO) can cause vision loss due t

108 Results of ocular biometric measurements in retinal vein occlusion (RVO) eyes are still inconclusive

109 the prevalence, pattern and risk factors of retinal vein occlusion (RVO) in an elderly population of

110 the treatment of macular edema secondary to retinal vein occlusion (RVO) in treatment-naive patients

111 PURPOSE OF REVIEW: Retinal vein occlusion (RVO) is a sight-threatening reti

112 ion (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson c

113 lopathy including diabetic retinopathy (DR), retinal vein occlusion (RVO), and neovascular-age relate

114 ents with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential

115 decreased visual acuity (VA) associated with retinal vein occlusion (RVO).

116 genotype, folate and vitamin B12 status, and retinal vein occlusion (RVO).

117 (CLS-TA), in eyes with macular edema due to retinal vein occlusion (RVO).

118 aturity (ROP), diabetic retinopathy (DR) and retinal vein occlusion (RVO).

119 r treatment of macular edema associated with retinal vein occlusion (RVO).

120 ), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeis

121 condary to AMD or Macular Edema Secondary to Retinal Vein Occlusion, Safety Assessment of Intravitrea

122 The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravi

123 the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE)-CRVO trial, CRUISE Study,

124 conditions, including diabetic retinopathy, retinal vein occlusion, sickle cell retinopathy, uveitis

125 The Collaborative Central Retinal Vein Occlusion Study has recently reported infor

126 ercept in Subjects with Macular Edema Due to Retinal Vein Occlusion (TANZANITE) study who received ei

127 2 patients, one each with Eales' disease and retinal vein occlusion the procedure was unsuccessful, n

128 te to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients wit

129 reference populations and patients in other retinal vein occlusion trials.

130 ORE2) and to compare with cohorts from other retinal vein occlusion trials.

131 mic diseases including diabetic retinopathy, retinal vein occlusion, uveitis, and HIV-related retinit

132 In retinal vein occlusion, venous pressures in a segmental

133 Central retinal vein occlusion was associated with an overall in

134 Retinal vein occlusion was observed in some Cbs(+/-) mou

135 tinal artery occlusion and 463 patients with retinal vein occlusion were enrolled and matched for age

136 two patients with macular edema secondary to retinal vein occlusion were enrolled in the study.

137 In 20 eyes of 10 pigs, branch retinal vein occlusions were created in a standardized m

138 Retinal vein occlusions were further divided into branch

139 e patients, 3 with branch and 9 with central retinal vein occlusion, were imaged in 27 sessions with

140 tic neuropathy in contrast to what occurs in retinal vein occlusion, where edema affects all retinal

141 eyes with macular edema secondary to central retinal vein occlusion, which were treated with a dexame

142 Treatment of macular edema secondary to retinal vein occlusion with ranibizumab has been shown t

143 rysm with subretinal hemorrhage (1), central retinal vein occlusion with vitreous hemorrhage (1), and